Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ809811-0,55
KB0,00
PKN64,0664,160,34
Msft-0,04
Nokia4,674,7495-0,30
IBM-0,26
Mercedes-Benz Group AG62,3662,38-0,21
PFE0,74
25.11.2022 23:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 25.11.2022
Orion (ORNAV.HE, Helsinki)
Závěr k 25.11.2022 Změna (%) Změna (EUR) Objem obchodů (EUR)
48,60 -0,31 -0,15 63 953
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.11.2022
Popis společnosti
Obecné informace
Název společnostiOrion Oyj
TickerORNBV
TickerORNAV
Kmenové akcie:Ordinary Shares Class B
Kmenové akcie:Ordinary Shares Class A
RICORNAV.HE
RICORNBV.HE
ISINFI0009014369
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.09.2022
Počet zaměstnanců k 30.09.2022 3 527
Akcie v oběhu k 27.10.2022 140 423 006
MěnaEUR
Kontaktní informace
UliceOrionintie 1A
MěstoESPOO
PSČ02200
ZeměFinland
Kontatní osobaJari Karlson
Funkce kontaktní osobyChief Financial Officer; Senior Vice President, Animal Health; Member of the Executive Management Board
Telefon 358 104 261
Fax358104264435
Kontatní telefon358 104 262 883

Business Summary: Orion Oyj, previously Orion Corporation, is a Finland-based company active within the pharmaceutical industry. The Company is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2022, Orion Oyj revenues increased 37% to EUR1.05B. Net income applicable to common stockholders increased 98% to EUR317.9M. Revenues reflect Proprietary Products segment increase of 85% to EUR530.5M, Specialty Products segment increase of 5% to EUR386.4M, North America segment increase from EUR63.4M to EUR299.5M, Other Europe segment increase of 13% to EUR298.3M.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Medicinal & Botanical Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Medicinal and Botanical Manufacturing
SICPharmaceutical Preparations
SICMedicinals And Botanicals



  • Poslední aktualizace: 26.11.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Nomination CommitteeHeikki Westerlund5527.04.202127.04.2021
President, Chief Executive Officer, Chairman of the Executive Management BoardTimo Lappalainen6001.01.200801.01.2008
Chief Financial Officer; Senior Vice President, Animal Health; Member of the Executive Management BoardJari Karlson5901.08.2002
Senior Vice President, Commercial Operations; Member of the Executive Management BoardSatu Ahomaki5401.10.201801.01.2008
Senior Vice President, Global Operations and Chairman of the Board of Fermion Oy; Member of the Executive Management BoardLiisa Hurme5301.01.201901.01.2008
Senior Vice President, Member of the Executive Management BoardJuhani Kankaanpaa-01.11.202201.11.2022
Senior Vice President, Specialty Products; Member of the Executive Management BoardVirve Laitinen4801.01.201901.01.2012
Senior Vice President, Animal Health business division, Member of the Executive Management BoardNiclas Lindstedt-01.01.202301.01.2023
Senior Vice President, Branded Products business division, Member of the Executive Management BoardHao Pan-01.01.202301.01.2023
Senior Vice President for Research and Development, Member of the Executive Management BoardOuti Vaarala5901.06.202001.06.2020